• Corpus ID: 39036781

Nodulocystic acne and hidradenitis suppurativa treated with acitretin: a case report.

  title={Nodulocystic acne and hidradenitis suppurativa treated with acitretin: a case report.},
  author={Andrew Scheman},
  volume={69 4},
Nodulocystic acne is a dermatologic disease that can result in significant damage to the skin of the face, chest, and back. Hidradenitis suppurativa is a scarring disease of the skin that causes deep cysts and abscesses on the axillae and anogenital areas. We review a case of a patient with severe nodulocystic facial acne and hidradenitis suppurativa that was treated with 2 full courses of isotretinoin. Although the patient's condition improved, some draining cysts persisted on the face and… 

Severe hidradenitis suppurativa treated with infliximab infusion.

A 17-year-old male patient with a 3-year history of hidradenitis suppurativa presented to the dermatology clinic for more effective treatment, with symptoms including groin and perineal pain, serous and purulent discharge, and malodor.

European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa

Hidradenitis suppurativa/acne inversa (HS) is a chronic, inflammatory, recurrent, debilitating skin disease of the hair follicle that usually presents after puberty with painful, deep‐seated,

Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment

This review focuses on the main features of HS, including epidemiology, clinical aspects, pathogenesis, severity classifications, comorbidities, and currently available treatments.

Medical and Surgical Treatment of Hidradenitis Suppurativa: A Review

The main features of HS are highlighted so that awareness of this disease might be heightened in primary care physicians and surgeons, who may be the first health care providers to see patients with this disease owing to its characteristic clinical presentation.

Medical Management of Hidradenitis Suppurativa with Non-Biologic Therapy: What’s New?

An update on non-biologic and non-interventional modalities published in 2019–2021 in the clinical management of HS is presented.

Update on hidradenitis suppurativa: connecting the tracts

Patients and physicians across multiple specialties must work together to expand awareness of and interest in HS, so that one day, individuals with HS can be freed from this crippling disease.

Painful Hidradenitis Suppurativa

A greater understanding of the diagnosis, pathophysiology, and potential treatment options for HS patients may help providers to be better able to contribute to care of patients with painful hidradenitis suppurativa.

Hidradenitis suppurativa/Acne inversa: an endocrine skin disorder?

The current view on the hormonal dysregulation and metabolic syndrome and their role in HS is described.

Facial Hidradenitis Suppurativa in a 28-Year-Old Male Responding to Finasteride

Finasteride, a competitive 5 -reductase inhibitor of type II, has proven effective in the treatment of HS lesions in some patients, and is normally used on patients over 40 years of age with a prostate pathology.

Long‐term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer?

The once-in-a-lifetime use of oral isotretinoin in the treatment of Hidradenitis suppurativa is suggested to be a viable option for the management of the disease.



Hidradenitis Suppurativa

Hidradenitis suppurativa should be suspected in young adults with recurrent, deep furuncular lesions in flexural sites, especially when such lesions respond poorly to antibiotic therapy.

Evaluation of isotretinoin treatment of hidradenitis suppurativa.

Acitretin : A Review of its Pharmacology and Therapeutic Use.

Acitretin has an established place in the treatment of keratinising disorders, although its use in women of child-bearing potential must be accompanied by effective contraceptive measures, with a further 2-year contraceptive period after therapy completion.

Acitretin: optimal dosing strategies.

  • M. Ling
  • Medicine
    Journal of the American Academy of Dermatology
  • 1999

Treatment of psoriasis. Part 2. Systemic therapies.

The array of systemic medications used in the treatment of psoriasis is rapidly expanding and dosage and monitoring recommendations in published literature are presented.

The retinoids. A review of their clinical pharmacology and therapeutic use.

The clinical pharmacology, mechanisms of action and therapeutic use of the retinoids, particularly isotretinoin (13-cis-retinoic acid) and etretinate, are reviewed and arotinoid ethylester (Ro 13-6298) has revealed the best anti-psoriatic and anti-inflammatory effects at extremely low dose levels.

Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide.

This study provides no evidence that use of isotretinoin is associated with an increased risk for depression, suicide, or other psychiatric disorders.